



For professional investors only. Past performance is no guarantee of future returns.

RHENMAN HEALTHCARE EQUITY L/S

November 2024	
IC1 (EUR)	RC1 (SEK)
2.51%	1.67%
YTD	
IC1 (EUR)	RC1 (SEK)
16.61%	19.74%



Monthly comment
Kaspar Hällsten
 Portfolio Manager (Medtech)

SUMMARY

Once the results of the US elections were in, focus shifted towards the economy. The potential implications of Trump's and the Republican's control of both the Senate and the House, and hence a higher likelihood of pushing through their political agenda, caused uncertainty around trade agreements and fiscal deficits for example. Within the eurozone deteriorating economic data raised fears of a deeper slowdown while the US economy demonstrated resilience. The healthcare sector had a tough month, largely due to the political uncertainty post US election.

MONTHLY COMMENT

November saw heightened volatility across financial markets, driven by the dramatic US election, Trump's victory, his controversial cabinet nominations, fluctuating interest rates and currencies, geopolitical tensions as well as the earnings season. Donald Trump secured both the Electoral College and the popular vote. Republicans gained control of the Senate and the House of Representatives, paving the way for a potential shift in policy direction. This outcome sparked a mix of optimism and uncertainty among investors.

Economic implications post-election

Markets quickly shifted their focus to the economic implications of Republican policies and the cabinet appointments once the election results were in. Trump's proposed agenda included significant tax cuts, deregulation, and stricter immigration policies. However, his 'America First' stance which is centered on renegotiating trade agreements and imposing higher tariffs to partially fund tax reductions, raised concerns about widening fiscal deficits. Trump's victory was well received by a large part of the business community, but at the same time some concerns around potential increased protectionism and trade conflicts with major trading partners were raised. Initial market reactions included a rise in long-term interest rates as investors priced in potential inflationary pressures.

Swift cabinet appointments

By month's end, Trump had announced nominations for all key cabinet positions, pending Senate approval. Notably, hedge fund veteran, Scott Bessent, was tapped as Treasury Secretary. Bessent's track record of fiscal conservatism and skepticism toward extensive tariffs suggested an effort to

reassure the markets and stabilize fiscal policy. Nevertheless, tensions regarding Trump's economic agenda remained apparent, leaving questions about how Bessent would manage competing priorities.

Eurozone showed signs of weakness

In the Eurozone, deteriorating economic data raised fears of a deeper slowdown, and a combination of rising wages and declining activity in manufacturing and services presented a challenge for the European Central Bank (ECB). Political deadlocks in key economies like Germany and France amplified uncertainty. Expectations for decisive ECB action rose which led to continued euro depreciation, with the currency reaching its lowest level since 2022.

US outperformance

In contrast with the Eurozone, the US economy demonstrated resilience, particularly in the services sector in November. This strength bolstered the dollar and drove interest rates higher early in the month. However, the rates eased later on following favorable inflation data, and the announcement of a moderate Treasury Secretary nominee.

Healthcare sector underperformed

The earnings season was overall good, with most sectors performing well. However, healthcare lagged, marking one of its weakest relative months in recent times. This underperformance mainly was linked to post-election uncertainty and Trump's nomination of industry critic Robert F. Kennedy Jr. as Health Secretary. Despite stable earnings reports, sector sentiment was negatively impacted.

Continued on the next page →

FUND PERFORMANCE

In November, the fund increased by 2.5% in the main share class IC1 (EUR). Post-election volatility was notable, but strong contributions from most sub-sectors, particularly medical technology, buoyed the overall performance. Top contributors were Natera and Boston Scientific. The worst contributors were Evolent Health and ESSA Pharma.

Strong month for Natera following quarterly report

Natera is active in genetic testing and specializes in cell-free DNA testing to offer insights within oncology, reproductive health and organ transplants. They published a strong earnings report during the month, which underlined an increased level of utilization and higher average prices for their flagship product, Signatera. The stock increased by almost 40 percent during November.

Boston Scientific presented promising data

Boston Scientific is a leading medtech company focusing on cardiovascular health. The company presented positive data from the OPTION trial which contributed to the stocks increase during the month. The trial, which met all primary endpoints, evaluated the company's product WATCHMAN FLX, a device used for the closure of the left atrial appendage and thereby becoming an alternative to the use of blood thinners after ablation in patients with atrial fibrillation. Furthermore, the trial demonstrated improved safety compared to standard of care. These results strengthened the market's belief in the company's potential to further increase its total addressable market.

Weak earnings for Evolent Health

Evolent Health is a tech-enabled specialty care management company, primarily focused on oncology and cardiology. During the month, the company released weak earnings results, primarily attributable to prior period developments. The stock reaction was unforgiving due to management's bullish tone on conferences, and news reports of apparent takeout interest – interest which seemed to have disappeared by the end of the month.

Disappointing study results for ESSA's pipeline candidate

ESSA Pharma develops therapeutics targeting prostate cancer. Focus has been on their lead candidate, masofaniten, which inhibits the androgen receptor. During the month, the company had a major setback when the ongoing Phase 2 trial in metastatic castrate-resistant prostate cancer was discontinued. In a pre-defined analysis, the efficacy was deemed insufficient which also caused uncertainty concerning the future development of masofaniten. Consequently, the stock fell during the month.

REFLECTIONS FROM THE MANAGERS

The healthcare sector had a particularly tough month relative to the stock market overall, but still ended the month up in euros. The sector has been struggling for a while, partly due to tech stocks performing so strongly and partly due to increasing uncertainty regarding potential cuts in healthcare spending following the American elections.



Henrik Rhenman
Founder/CIO

Concerns within the investor community

Donald Trump's nomination of Robert F Kennedy Jr to serve as US secretary of health and human services, and the establishment of the DOGE group, with entrepreneurs Elon Musk and Vivek Ramaswamy at the helm has caused concern within the investor community. The potential policy adjustments and spending cuts are seen as negative for the pharmaceutical industry. Additionally, cuts to the federal grants towards Medicaid are also being contemplated. The main concerns in the short term are how much any potential changes would mean lower total compensation to the hospitals, and also how much markets for the insurance companies operating in Medicaid would worsen.

Vaccinations and related guidelines, documentation, and side effects are controversial for many Americans and there are many skeptics, primarily among Republicans. They feel heard and represented by RFK. However, any major changes in the short term are unlikely.

We still believe the sector has potential to deliver

The interest in cyclical stocks seems to be increasing, while defensives, such as healthcare stocks, are not currently viewed by the broader investor group as likely 2025 winners. In our view, valuations are attractive, and that the sector has the potential to deliver positive news flow in the coming year. The fact that it is not the most favored sector, could in fact be a blessing in disguise. Low expectations combined with good prospects to perform well is something which makes us more comfortable and ought to lead to good risk/reward. If interest rates continue to come down, which is our main scenario, small and midcap stocks could come back into favor.

Fund characteristics

KIID AND PROSPECTUS (WEBPAGE)

<https://fundinfo.fundrock.com/RhenmanPartnersFund/>

INVESTABLE CURRENCIES

Euro (EUR) / Swedish Krona (SEK) / US Dollar (USD)

TARGET FUND SIZE

The Fund Management Company may decide on hard closure when AUM has reached EUR 1bn

RETURN TARGET

Annualised net returns in excess of 12% over time

LEGAL STRUCTURE

AIF / FCP (Fonds Commun de Placement) under Part II of the Luxembourg Law on Investment Funds

PORTFOLIO MANAGER

Rhenman & Partners Asset Management AB

INVESTMENT TEAM

Henrik Rhenman, Kaspar Hällsten, Hugo Schmidt, Amennai Beyeen and Camilla Oxhamre Cruse

AIFM / MANAGEMENT COMPANY

FundRock Management Company S.A.

PRIME BROKER

Skandinaviska Enskilda Banken AB (publ)

DEPOSITARY AND PAYING AGENT

Skandinaviska Enskilda Banken S.A.

AUDITOR

PricewaterhouseCoopers (PwC)

SUBSCRIPTION/REDEMPTION

Monthly

MINIMUM TOP UP

No minimum

NOTICE PERIOD

3 working days (12.00 CET)

HURDLE RATE

Euribor 90D (high-water mark)

+16%
annualised return since inception

PAST PERFORMANCE IS NO GUARANTEE OF FUTURE RETURNS.

FUND PERFORMANCE – IC1 (EUR)




NOVEMBER 2024


SHARE CLASS	NAV	MONTHLY RETURN	YEAR TO DATE	SINCE INCEPTION ¹
IC1 (EUR)	1015.97	2.51%	16.61%	915.97%
IC3 (EUR)	1309.04	2.57%	18.63%	1209.04%
IC2 (SEK)	849.20	1.76%	20.59%	749.20%
ID1 (SEK) - Distributing	486.35	1.71%	15.30%	386.35%
IC1 (USD)	242.30	-0.28%	12.53%	142.30%
IC2 (USD)	335.41	-0.25%	12.68%	235.41%
RC1 (EUR)	864.99	2.46%	16.37%	764.99%
RC1 (SEK)	978.46	1.67%	19.74%	878.46%
RC2 (SEK)	1045.98	1.71%	20.14%	945.98%
3M Euribor (EUR)	110.49	0.27%	3.48%	10.49%

Note: 1) Please find launch date information on page 5–10.

PORTFOLIO CONSTRUCTION²



CURRENCY EXPOSURE³



RISK (IC1 EUR)

Value at risk ⁴	2.24%
Standard Deviation ⁵	20.39%
Sharpe Ratio ⁵	0.77

EXPOSURE

Long	169%
Short	23%
Gross	191%
Net	146%

AUM

Fund:
EUR 791m
USD 835m

LARGEST LONG POSITIONS

1. Procept Biorobotics Corp
2. Boston Scientific Corp
3. Intuitive Surgical Inc
4. Eli Lilly & Co
5. Regeneron Pharmaceuticals Inc

SHARE CLASS CHARACTERISTICS – INSTITUTIONAL SHARE CLASSES – ONLY INSTITUTIONAL INVESTORS⁶

MINIMUM INVESTMENT		MGT. FEE	PERF. FEE	ISIN NO.	BLOOMBERG TICKER	LIPPER REUTERS	TELEKURS
IC1 (EUR)	250 000	1.50 %	20 %	LU0417598108	RHLEIC1 LX	65147588	10034579
IC2 (SEK)	50 000 000	1.00 %	20 %	LU0417598793	RHHIC2S LX	68204997	20323930
ID1 (SEK) - Distributing	100 000	1.50 %	20 %	LU0417599098	RHHCID1 LX	68153820	18491109
IC1 (USD)	300 000	1.50 %	20 %	LU0417598280	RHUIC1A LX	68305812	26812813
IC2 (USD)	6 000 000	1.00 %	20 %	LU0417598520	RHUIC2U LX	68265724	24456000

SHARE CLASS CHARACTERISTICS – RETAIL SHARE CLASSES – ALSO OPEN TO INSTITUTIONAL INVESTORS⁶

MINIMUM INVESTMENT		MGT. FEE	PERF. FEE	ISIN NO.	BLOOMBERG TICKER	LIPPER REUTERS	TELEKURS
RC1 (EUR)	2 500	2.00 %	20 %	LU0417597555	RHLERC1 LX	65147589	10034567
RC1 (SEK)	500	2.00 %	20 %	LU0417597712	RHLSRC1 LX	68014067	10239523
RC2 (SEK)	2 500 000	1.50 %	20 %	LU0417598017	RHLSRC2 LX	68015239	10239528

Notes: 2) Number of long equity positions (excluding any ETFs). 3) As a percentage of the market value of the long and short positions (excluding cash positions). 4) For holdings at month end (95 % conf. int. 250 days history). 5) Standard Deviation and Sharpe Ratio are annualised. 6) Administrative fees are charged in addition to the fees above. Further information is available in the KIID as well as the prospectus (part B. A14-18).

NAV & PERFORMANCE DATA

IC1 (EUR) NAV													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	
2009						100.75	105.19	107.47	107.83	100.99	105.70	113.28	
2010	117.91	119.94	127.53	122.31	108.73	106.40	102.84	102.63	109.95	112.16	116.17	122.73	
2011	121.53	124.28	123.35	127.79	134.24	129.26	128.19	119.36	118.28	125.67	127.48	134.59	
2012	142.42	143.99	149.51	150.29	150.07	159.07	160.74	160.74	165.47	156.93	161.34	158.92	
2013	168.92	178.11	191.91	198.41	209.10	202.53	225.87	223.66	233.45	225.66	246.67	246.79	
2014	263.91	277.13	262.34	247.80	260.99	274.87	276.25	296.82	304.03	326.16	338.66	352.48	
2015	391.34	419.34	448.65	421.01	463.44	456.29	476.60	424.39	370.76	401.72	430.21	423.32	
2016	345.01	326.39	325.66	342.05	366.15	355.48	389.06	378.89	385.50	340.52	369.37	372.46	
2017	391.88	436.08	454.95	456.28	415.30	455.96	449.05	468.44	473.40	468.37	491.88	501.07	
2018	535.61	535.64	525.88	523.61	556.39	554.68	578.66	618.36	613.63	543.46	570.43	475.31	
2019	543.40	556.92	548.98	516.00	512.38	564.44	581.75	557.75	527.02	561.13	633.91	666.08	
2020	638.10	617.80	526.64	616.09	683.34	688.66	663.00	689.52	719.57	700.26	744.64	780.13	
2021	790.43	794.91	823.74	837.54	828.70	870.48	858.50	875.26	834.83	880.80	805.89	880.28	
2022	776.72	780.60	824.28	786.93	751.19	768.25	834.69	825.88	800.44	844.40	866.06	807.64	
2023	823.92	806.09	783.66	809.73	820.97	834.77	816.47	819.04	794.43	751.08	804.10	871.27	
2024	920.56	963.96	995.30	954.50	968.96	988.88	1019.92	1073.64	1038.71	991.11	1015.97		

IC1 (EUR) PERFORMANCE % NET OF FEES													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	TOTAL
2009						0.75	4.41	2.17	0.33	-6.34	4.66	7.17	13.28
2010	4.09	1.72	6.33	-4.09	-11.10	-2.14	-3.35	-0.20	7.13	2.01	3.58	5.65	8.34
2011	-0.98	2.26	-0.75	3.60	5.05	-3.71	-0.83	-6.89	-0.90	6.25	1.44	5.58	9.66
2012	5.82	1.10	3.83	0.52	-0.15	6.00	1.05	0.00	2.94	-5.16	2.81	-1.50	18.08
2013	6.29	5.44	7.75	3.39	5.39	-3.14	11.52	-0.98	4.38	-3.34	9.31	0.05	55.29
2014	6.94	5.01	-5.34	-5.54	5.32	5.32	0.50	7.45	2.43	7.28	3.83	4.08	42.83
2015	11.02	7.15	6.99	-6.16	10.08	-1.54	4.45	-10.95	-12.64	8.35	7.09	-1.60	20.10
2016	-18.50	-5.40	-0.22	5.03	7.05	-2.91	9.45	-2.61	1.74	-11.67	8.47	0.84	-12.01
2017	5.21	11.28	4.33	0.29	-8.98	9.79	-1.52	4.32	1.06	-1.06	5.02	1.87	34.53
2018	6.89	0.01	-1.82	-0.43	6.26	-0.31	4.32	6.86	-0.76	-11.44	4.96	-16.68	-5.14
2019	14.33	2.49	-1.43	-6.01	-0.61	10.06	3.07	-4.13	-5.51	6.47	12.97	5.07	40.14
2020	-4.20	-3.18	-14.76	16.99	10.92	0.78	-3.73	4.00	4.36	-2.68	6.34	4.77	17.12
2021	1.32	0.57	3.63	1.68	-1.06	5.04	-1.38	1.95	-4.62	5.51	-8.50	9.23	12.84
2022	-11.76	0.50	5.60	-4.53	-4.54	2.27	8.65	-1.06	-3.08	5.49	2.57	-6.75	-8.25
2023	2.02	-2.16	-2.78	3.33	1.39	1.68	-2.19	0.31	-3.00	-5.46	7.06	8.35	7.88
2024	5.66	4.71	3.25	-4.10	1.51	2.06	3.14	5.27	-3.25	-4.58	2.51		16.61

IC2 (SEK) NAV													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	
2013	105.95	109.53	117.11	123.34	131.02	128.83	142.56	142.09	147.55	144.39	159.03	158.77	
2014	169.27	178.14	170.53	162.83	172.56	182.30	184.56	197.44	201.10	218.77	227.47	240.91	
2015	264.32	283.76	300.86	285.57	313.96	305.90	326.08	292.97	252.07	273.89	288.10	281.94	
2016	232.96	221.76	219.09	228.93	248.02	243.80	270.79	263.91	270.85	245.87	263.97	260.88	
2017	270.49	305.07	315.32	318.79	294.29	318.16	310.91	322.70	331.45	331.49	352.83	356.33	
2018	379.63	389.78	388.65	395.52	411.90	415.07	427.79	469.65	455.95	404.87	423.30	347.14	
2019	406.48	421.85	412.16	396.62	392.47	430.52	448.78	435.24	408.30	436.13	481.44	504.24	
2020	491.15	474.02	413.07	475.86	516.97	520.68	495.17	514.21	546.00	524.67	552.98	572.33	
2021	583.10	589.73	613.94	621.26	612.41	644.11	639.21	650.92	618.52	641.78	601.99	660.56	
2022	592.42	603.74	623.77	593.51	575.08	601.48	634.40	645.80	636.73	672.32	689.70	658.78	
2023	682.48	654.51	648.37	672.54	694.10	712.97	685.01	705.56	663.29	643.75	667.37	704.20	
2024	747.42	781.16	827.58	807.12	797.42	809.42	852.20	881.36	850.88	834.55	849.20		

NAV & PERFORMANCE DATA

IC2 (SEK) PERFORMANCE %. NET OF FEES													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	TOTAL
2013	5.95	3.38	6.92	5.32	6.23	-1.67	10.66	-0.33	3.84	-2.14	10.14	-0.16	58.77
2014	6.61	5.24	-4.27	-4.52	5.98	5.64	1.24	6.98	1.85	8.79	3.98	5.91	51.74
2015	9.72	7.35	6.03	-5.08	9.94	-2.57	6.60	-10.15	-13.96	8.66	5.19	-2.14	17.03
2016	-17.37	-4.81	-1.20	4.49	8.34	-1.70	11.07	-2.54	2.63	-9.22	7.36	-1.17	-7.47
2017	3.68	12.78	3.36	1.10	-7.69	8.11	-2.28	3.79	2.71	0.01	6.44	0.99	36.59
2018	6.54	2.67	-0.29	1.77	4.14	0.77	3.06	9.79	-2.92	-11.20	4.55	-17.99	-2.58
2019	17.09	3.78	-2.30	-3.77	-1.05	9.70	4.24	-3.02	-6.19	6.82	10.39	4.74	45.26
2020	-2.60	-3.49	-12.86	15.20	8.64	0.72	-4.90	3.85	6.18	-3.91	5.40	3.50	13.50
2021	1.88	1.14	4.11	1.19	-1.42	5.18	-0.76	1.83	-4.98	3.76	-6.20	9.73	15.42
2022	-10.32	1.91	3.32	-4.85	-3.11	4.59	5.47	1.80	-1.40	5.59	2.59	-4.48	-0.27
2023	3.60	-4.10	-0.94	3.73	3.21	2.72	-3.92	3.00	-5.99	-2.95	3.67	5.52	6.89
2024	6.14	4.51	5.94	-2.47	-1.20	1.50	5.29	3.42	-3.46	-1.92	1.76		20.59

IC1 (USD) NAV													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	TOTAL
2015		106.43	109.37	107.12	114.84	114.48	118.78	107.70	93.74	100.50	102.88	104.09	
2016	84.51	80.27	84.02	88.68	92.24	89.25	98.50	95.48	98.04	84.48	88.63	88.85	
2017	95.78	104.78	110.08	112.50	105.65	116.97	118.72	124.26	125.01	121.84	130.74	133.94	
2018	147.42	145.05	143.28	140.20	145.38	144.95	151.45	161.13	159.77	138.04	144.79	121.78	
2019	139.80	142.16	138.18	129.63	128.10	144.08	145.20	137.69	128.80	140.32	157.94	168.74	
2020	159.56	153.04	130.41	152.12	171.72	174.40	176.32	183.59	188.70	182.40	198.45	211.68	
2021	213.30	214.24	216.35	224.27	224.74	230.35	227.21	230.77	215.94	228.14	202.28	223.90	
2022	194.84	196.20	205.23	185.74	180.08	179.80	190.49	185.80	175.47	186.77	199.49	192.90	
2023	200.22	191.26	190.52	200.02	195.88	203.77	201.41	198.92	188.22	177.65	196.27	215.32	
2024	224.18	236.31	244.30	232.03	239.08	240.88	250.80	268.84	261.87	242.99	242.30		

IC1 (USD) PERFORMANCE %. NET OF FEES													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	TOTAL
2015		6.43	2.76	-2.06	7.21	-0.31	3.76	-9.33	-12.96	7.21	2.37	1.18	4.09
2016	-18.81	-5.02	4.67	5.55	4.01	-3.24	10.36	-3.07	2.68	-13.83	4.91	0.25	-14.64
2017	7.80	9.40	5.06	2.20	-6.09	10.71	1.50	4.67	0.60	-2.54	7.30	2.45	50.75
2018	10.06	-1.61	-1.22	-2.15	3.69	-0.30	4.48	6.39	-0.84	-13.60	4.89	-15.89	-9.08
2019	14.80	1.69	-2.80	-6.19	-1.18	12.47	0.78	-5.17	-6.46	8.94	12.56	6.84	38.56
2020	-5.44	-4.09	-14.79	16.65	12.88	1.56	1.10	4.12	2.78	-3.34	8.80	6.67	25.45
2021	0.77	0.44	0.98	3.66	0.21	2.50	-1.36	1.57	-6.43	5.65	-11.34	10.69	5.77
2022	-12.98	0.70	4.60	-9.50	-3.05	-0.16	5.95	-2.46	-5.56	6.44	6.81	-3.30	-13.85
2023	3.79	-4.48	-0.39	4.99	-2.07	4.03	-1.16	-1.24	-5.38	-5.62	10.48	9.71	11.62
2024	4.11	5.41	3.38	-5.02	3.04	0.75	4.12	7.19	-2.59	-7.21	-0.28		12.53

IC2 (USD) NAV													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	TOTAL
2014					102.92	108.60	106.82	113.71	112.69	120.10	124.21	126.40	
2015	132.75	141.32	145.96	143.02	153.38	152.95	158.76	143.26	124.74	133.79	137.03	138.70	
2016	112.66	107.07	112.12	118.40	123.21	119.27	131.69	127.71	131.20	113.12	118.73	119.08	
2017	128.42	140.54	147.72	151.02	141.89	156.98	159.38	166.89	167.94	163.77	175.76	180.12	
2018	198.33	195.19	192.99	188.92	195.95	195.44	204.27	217.39	215.63	186.38	195.57	164.56	
2019	188.99	192.24	186.93	175.43	173.45	195.16	196.77	186.66	174.69	190.39	214.39	228.86	
2020	216.50	207.73	177.09	206.66	233.28	237.07	239.75	249.75	256.77	248.30	270.22	288.47	
2021	290.77	292.16	295.14	306.04	306.71	314.48	310.32	315.27	295.18	311.98	276.74	306.45	
2022	266.79	268.75	281.24	254.63	246.97	246.70	261.47	255.15	241.06	256.69	274.29	265.33	
2023	275.53	263.30	262.39	275.58	270.00	280.99	277.84	274.54	259.87	245.38	271.21	297.66	
2024	310.04	326.96	337.22	320.42	330.30	332.92	346.67	371.73	362.21	336.25	335.41		

NAV & PERFORMANCE DATA

IC2 (USD) PERFORMANCE % NET OF FEES													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	TOTAL
2014					2.92	5.52	-1.64	6.45	-0.90	6.58	3.42	1.76	26.40
2015	5.02	6.46	3.28	-2.01	7.24	-0.28	3.80	-9.76	-12.93	7.26	2.42	1.22	9.73
2016	-18.77	-4.96	4.72	5.60	4.06	-3.20	10.41	-3.02	2.73	-13.78	4.96	0.29	-14.15
2017	7.84	9.44	5.11	2.23	-6.05	10.63	1.53	4.71	0.63	-2.48	7.32	2.48	51.26
2018	10.11	-1.58	-1.13	-2.11	3.72	-0.26	4.52	6.42	-0.81	-13.56	4.93	-15.86	-8.64
2019	14.85	1.72	-2.76	-6.15	-1.13	12.52	0.82	-5.14	-6.41	8.99	12.61	6.75	39.07
2020	-5.40	-4.05	-14.75	16.70	12.88	1.62	1.13	4.17	2.81	-3.30	8.83	6.75	26.05
2021	0.80	0.48	1.02	3.69	0.22	2.53	-1.32	1.60	-6.37	5.69	-11.30	10.74	6.23
2022	-12.94	0.73	4.65	-9.46	-3.01	-0.11	5.99	-2.42	-5.52	6.48	6.86	-3.27	-13.42
2023	3.84	-4.44	-0.35	5.03	-2.02	4.07	-1.12	-1.19	-5.34	-5.58	10.53	9.75	12.18
2024	4.16	5.46	3.14	-4.98	3.08	0.79	4.13	7.23	-2.56	-7.17	-0.25		12.68

IC3 (EUR) NAV													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	
2009								102.15	103.33	96.78	101.30	109.19	
2010	114.20	116.43	124.73	119.62	106.33	104.06	100.57	100.37	107.52	109.68	113.59	120.00	
2011	118.82	121.50	120.59	124.92	131.89	126.43	125.36	116.73	115.66	122.76	124.53	132.03	
2012	140.67	142.42	148.58	149.43	149.16	159.24	161.09	161.06	166.38	157.79	162.21	159.79	
2013	170.25	180.70	196.39	203.85	216.23	208.50	235.66	233.03	244.50	236.34	260.09	260.40	
2014	280.76	296.58	279.47	263.97	278.02	294.48	296.09	321.00	329.83	356.89	372.31	389.50	
2015	437.99	471.80	508.68	477.10	527.32	518.14	544.00	481.68	420.82	455.95	488.29	480.47	
2016	391.59	370.46	369.62	388.23	415.58	403.47	441.58	430.05	437.55	386.50	419.24	422.75	
2017	444.79	494.96	516.44	518.14	471.42	517.72	509.84	533.67	539.99	534.17	563.68	575.38	
2018	620.04	620.31	607.45	604.83	647.20	644.96	676.32	728.69	722.85	640.18	671.96	559.91	
2019	640.11	656.04	646.69	607.84	604.10	664.90	685.30	657.02	620.83	661.00	750.14	793.38	
2020	760.50	736.47	628.21	735.37	818.48	825.74	795.41	827.79	868.81	845.83	903.59	953.10	
2021	967.72	974.32	1014.44	1034.11	1022.41	1081.10	1066.84	1089.00	1038.74	1097.93	1003.87	1098.35	
2022	969.75	975.16	1030.38	984.28	940.19	962.14	1045.97	1035.63	1004.35	1060.18	1088.05	1015.28	
2023	1036.43	1014.58	986.98	1020.40	1035.26	1053.32	1030.88	1034.78	1004.29	950.12	1017.81	1103.49	
2024	1165.88	1227.98	1273.13	1221.75	1241.07	1267.30	1309.41	1387.29	1336.70	1276.25	1309.04		

IC3 (EUR) PERFORMANCE % NET OF FEES													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	TOTAL
2009								2.15	1.16	-6.34	4.67	7.79	9.19
2010	4.59	1.95	7.13	-4.10	-11.11	-2.13	-3.35	-0.20	7.12	2.01	3.56	5.64	9.90
2011	-0.98	2.26	-0.75	3.59	5.58	-4.14	-0.85	-6.88	-0.92	6.14	1.44	6.02	10.03
2012	6.54	1.24	4.33	0.57	-0.18	6.76	1.16	-0.02	3.30	-5.16	2.80	-1.49	21.03
2013	6.55	6.14	8.68	3.80	6.07	-3.57	13.03	-1.12	4.92	-3.34	10.05	0.12	62.96
2014	7.82	5.63	-5.77	-5.55	5.32	5.92	0.55	8.41	2.75	8.20	4.32	4.62	49.58
2015	12.45	7.72	7.82	-6.21	10.53	-1.74	4.99	-11.46	-12.63	8.35	7.09	-1.60	23.36
2016	-18.50	-5.40	-0.23	5.03	7.04	-2.91	9.45	-2.61	1.74	-11.67	8.47	0.84	-12.01
2017	5.21	11.28	4.34	0.33	-9.02	9.82	-1.52	4.67	1.18	-1.08	5.52	2.08	36.10
2018	7.76	0.04	-2.07	-0.43	7.01	-0.35	4.86	7.74	-0.80	-11.44	4.96	-16.68	-2.69
2019	14.32	2.49	-1.43	-6.01	-0.62	10.06	3.07	-4.13	-5.51	6.47	13.49	5.76	41.70
2020	-4.14	-3.16	-14.70	17.06	11.30	0.89	-3.67	4.07	4.96	-2.64	6.83	5.48	20.13
2021	1.53	0.68	4.12	1.94	-1.13	5.74	-1.32	2.08	-4.62	5.70	-8.57	9.41	15.24
2022	-11.71	0.56	5.66	-4.47	-4.48	2.33	8.71	-0.99	-3.02	5.56	2.63	-6.69	-7.56
2023	2.08	-2.11	-2.72	3.39	1.46	1.74	-2.13	0.38	-2.95	-5.39	7.12	8.42	8.69
2024	5.65	5.33	3.68	-4.04	1.58	2.11	3.32	5.95	-3.65	-4.52	2.57		18.63

NAV & PERFORMANCE DATA

ID1 (SEK) NAV – DISTRIBUTING												
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
2012					100.64	104.51	101.00	100.77	105.42	101.93	105.47	103.07
2013	109.66	109.21	116.69	122.83	130.33	127.88	141.46	140.87	146.24	143.04	157.52	157.19
2014	167.54	168.39	161.54	154.18	163.36	172.51	174.59	186.71	190.10	206.73	214.90	227.49
2015	249.52	256.41	271.30	257.41	282.93	275.68	293.76	263.61	226.72	246.24	258.91	253.27
2016	209.19	186.39	184.08	192.27	208.21	204.58	227.14	221.28	227.01	205.99	221.08	218.41
2017	226.36	247.58	257.17	259.92	239.81	259.22	253.21	262.73	269.78	269.72	287.00	289.42
2018	308.23	298.96	297.90	303.06	315.52	317.84	327.46	359.38	348.18	309.03	322.97	264.75
2019	309.87	310.87	303.62	292.04	288.86	316.74	330.03	319.94	300.01	320.32	354.05	370.83
2020	361.05	329.78	287.25	330.78	359.59	362.02	344.14	357.22	379.24	364.27	383.82	397.12
2021	404.46	389.12	404.96	409.65	403.63	424.45	421.05	428.64	407.07	422.21	395.86	434.40
2022	389.43	379.34	391.75	372.61	360.89	377.30	397.79	404.74	398.86	421.65	432.38	412.08
2023	427.53	393.44	389.58	404.69	417.81	428.14	411.17	423.32	397.80	385.92	399.91	421.81
2024	447.76	448.84	475.34	463.37	457.61	464.31	488.79	505.35	487.72	478.16	486.35	

ID1 (SEK) PERFORMANCE %. NET OF FEES – DISTRIBUTING													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	TOTAL
2012					0.64	3.85	-3.36	-0.23	4.61	-3.31	3.47	-2.28	3.07
2013	6.39	-0.41	6.85	5.26	6.11	-1.88	10.62	-0.42	3.81	-2.19	10.12	-0.21	52.51
2014	6.58	0.51	-4.07	-4.56	5.95	5.60	1.21	6.94	1.82	8.75	3.95	5.86	44.72
2015	9.68	2.76	5.81	-5.12	9.91	-2.56	6.56	-10.26	-13.99	8.61	5.15	-2.18	11.33
2016	-17.40	-10.90	-1.24	4.45	8.29	-1.74	11.03	-2.58	2.59	-9.26	7.33	-1.21	-13.76
2017	3.64	9.37	3.87	1.07	-7.74	8.09	-2.32	3.76	2.68	-0.02	6.41	0.84	32.51
2018	6.50	-3.01	-0.35	1.73	4.11	0.74	3.03	9.75	-3.12	-11.24	4.51	-18.03	-8.52
2019	17.04	0.32	-2.33	-3.81	-1.09	9.65	4.20	-3.06	-6.23	6.77	10.53	4.74	40.07
2020	-2.64	-8.66	-12.90	15.15	8.71	0.68	-4.94	3.80	6.16	-3.95	5.37	3.47	7.09
2021	1.85	-3.79	4.07	1.16	-1.47	5.16	-0.80	1.80	-5.03	3.72	-6.24	9.74	9.39
2022	-10.35	-2.59	3.27	-4.89	-3.45	4.55	5.43	1.75	-1.45	5.71	2.54	-4.69	-5.14
2023	3.75	-7.97	-0.98	3.88	3.24	2.47	-3.96	2.95	-6.03	-2.99	3.63	5.48	2.36
2024	6.15	0.24	5.90	-2.52	-1.24	1.46	5.27	3.39	-3.49	-1.96	1.71		15.30

RC1 (EUR) NAV												
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
2010									104.35	104.75	110.36	115.32
2011	114.18	116.50	115.79	119.40	125.10	120.47	119.15	110.91	109.86	116.68	118.31	124.92
2012	132.14	133.59	138.66	139.34	139.09	147.39	148.89	148.83	153.16	145.20	149.21	146.92
2013	156.14	164.59	177.28	183.22	192.89	185.65	206.96	204.86	212.69	205.49	224.58	224.79
2014	240.30	251.66	236.42	223.21	235.00	247.45	248.60	266.95	273.34	293.13	304.24	315.14
2015	349.47	373.47	398.19	373.48	411.03	404.45	422.31	375.75	328.13	355.37	380.41	374.15
2016	304.81	288.23	287.45	301.80	322.91	313.37	342.82	333.71	339.38	299.66	324.90	327.48
2017	344.40	383.08	399.53	400.83	364.36	400.14	393.87	411.29	415.46	410.84	431.35	439.53
2018	469.64	469.79	461.25	459.04	487.65	485.62	506.41	540.96	536.85	475.23	498.59	415.26
2019	474.53	486.14	479.01	450.01	447.04	491.82	506.66	485.54	458.58	488.03	551.77	579.39
2020	554.79	536.92	457.48	534.95	593.35	597.63	575.10	597.94	623.77	606.76	645.03	675.64
2021	684.33	687.99	712.68	724.36	716.46	752.31	741.63	755.89	720.53	760.15	694.94	759.14
2022	669.52	672.59	709.89	677.44	646.36	660.75	717.58	709.66	687.50	724.92	743.19	692.75
2023	706.38	690.81	671.28	693.32	702.60	714.10	698.12	700.00	678.68	641.35	686.31	743.32
2024	786.28	823.53	850.03	814.78	826.76	843.40	869.75	915.24	885.14	844.19	864.99	

*Please note that February's NAV for ID1 (SEK) has been reduced by dividends determined annually.

NAV & PERFORMANCE DATA

RC1 (EUR) PERFORMANCE % NET OF FEES													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	TOTAL
2010									4.35	0.38	5.36	4.49	15.32
2011	-0.99	2.03	-0.61	3.12	4.77	-3.70	-1.10	-6.92	-0.95	6.21	1.40	5.59	8.32
2012	5.78	1.10	3.80	0.49	-0.18	5.97	1.02	-0.04	2.91	-5.20	2.76	-1.53	17.61
2013	6.28	5.41	7.71	3.35	5.28	-3.75	11.48	-1.01	3.82	-3.39	9.29	0.09	53.00
2014	6.90	4.73	-6.06	-5.59	5.28	5.30	0.46	7.38	2.39	7.24	3.80	3.58	40.19
2015	10.89	6.87	6.62	-6.21	10.05	-1.60	4.42	-11.03	-12.67	8.30	7.05	-1.65	18.73
2016	-18.53	-5.44	-0.27	4.99	6.99	-2.95	9.40	-2.66	1.70	-11.70	8.42	0.79	-12.47
2017	5.17	11.23	4.29	0.33	-9.10	9.82	-1.57	4.42	1.01	-1.11	4.99	1.90	34.22
2018	6.85	0.03	-1.82	-0.48	6.23	-0.42	4.28	6.82	-0.76	-11.48	4.92	-16.71	-5.52
2019	14.27	2.45	-1.47	-6.05	-0.66	10.02	3.02	-4.17	-5.55	6.42	13.06	5.01	39.52
2020	-4.25	-3.22	-14.80	16.93	10.92	0.72	-3.77	3.97	4.32	-2.73	6.31	4.75	16.61
2021	1.29	0.53	3.59	1.64	-1.09	5.00	-1.42	1.92	-4.68	5.50	-8.58	9.24	12.36
2022	-11.81	0.46	5.55	-4.57	-4.59	2.23	8.60	-1.10	-3.12	5.44	2.52	-6.79	-8.75
2023	1.97	-2.20	-2.83	3.28	1.34	1.64	-2.24	0.27	-3.05	-5.50	7.01	8.31	7.30
2024	5.78	4.74	3.22	-4.15	1.47	2.01	3.12	5.23	-3.29	-4.63	2.46		16.37

RC1 (SEK) NAV													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	
2009						99.74	99.92	101.00	101.51	96.72	101.85	106.75	
2010	110.70	108.05	115.09	109.18	96.69	93.87	89.69	88.93	93.37	96.59	98.29	102.16	
2011	98.91	100.22	101.80	105.28	111.04	109.04	107.03	100.09	100.29	104.24	106.42	111.05	
2012	118.78	118.87	123.79	125.05	125.79	130.61	126.17	125.85	131.65	127.25	131.60	128.55	
2013	136.76	141.24	150.89	158.78	168.47	165.25	182.72	181.89	188.61	184.41	203.02	202.38	
2014	215.63	226.61	216.26	206.33	218.55	230.73	233.43	249.55	253.98	276.09	286.74	302.97	
2015	332.20	356.11	376.45	357.02	392.32	381.98	406.89	365.09	313.86	340.74	358.11	350.16	
2016	289.10	274.97	271.43	283.40	306.76	301.29	334.38	325.60	333.90	302.85	324.90	320.85	
2017	332.37	374.59	388.12	392.14	361.60	390.79	381.55	395.80	406.28	406.01	431.88	435.88	
2018	464.01	476.10	474.20	482.24	501.86	505.35	520.45	570.92	553.64	491.16	513.08	420.40	
2019	491.82	510.01	497.89	478.68	473.25	518.71	540.21	523.46	490.63	523.61	578.90	605.94	
2020	589.68	568.66	495.10	569.86	619.10	623.04	591.99	614.21	651.95	625.95	659.35	681.93	
2021	694.29	701.75	730.01	738.19	726.89	764.25	757.79	771.23	731.97	758.87	711.17	780.47	
2022	699.34	712.15	735.11	698.88	676.59	707.04	745.13	757.76	746.43	788.79	808.57	770.05	
2023	798.90	763.61	755.79	784.76	810.22	831.67	798.34	821.56	771.71	748.29	775.08	817.18	
2024	867.57	906.18	959.27	934.66	922.61	935.74	984.96	1017.99	982.06	962.38	978.46		

RC1 (SEK) PERFORMANCE % NET OF FEES													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	TOTAL
2009						-0.26	0.18	1.08	0.50	-4.72	5.30	4.81	6.75
2010	3.70	-2.39	6.52	-5.14	-11.44	-2.92	-4.45	-0.85	4.99	3.45	1.76	3.94	-4.30
2011	-3.18	1.32	1.58	3.42	5.47	-1.80	-1.84	-6.48	0.20	3.94	2.09	4.35	8.70
2012	6.96	0.08	4.14	1.02	0.59	3.83	-3.40	-0.25	4.61	-3.34	3.42	-2.32	15.76
2013	6.39	3.28	6.83	5.23	6.10	-1.91	10.57	-0.45	3.69	-2.23	10.09	-0.32	57.43
2014	6.55	5.09	-4.57	-4.59	5.92	5.57	1.17	6.91	1.78	8.71	3.86	5.66	49.70
2015	9.65	7.20	5.71	-5.16	9.89	-2.64	6.52	-10.27	-14.03	8.56	5.10	-2.22	15.58
2016	-17.44	-4.89	-1.29	4.41	8.24	-1.78	10.98	-2.63	2.55	-9.30	7.28	-1.25	-8.37
2017	3.59	12.70	3.61	1.04	-7.79	8.07	-2.36	3.73	2.65	-0.07	6.37	0.93	35.85
2018	6.45	2.61	-0.40	1.70	4.07	0.70	2.99	9.70	-3.03	-11.29	4.46	-18.06	-3.55
2019	16.99	3.70	-2.38	-3.86	-1.13	9.61	4.14	-3.10	-6.27	6.72	10.56	4.67	44.13
2020	-2.68	-3.56	-12.94	15.10	8.64	0.64	-4.98	3.75	6.14	-3.99	5.34	3.42	12.54
2021	1.81	1.07	4.03	1.12	-1.53	5.14	-0.85	1.77	-5.09	3.68	-6.29	9.74	14.45
2022	-10.40	1.83	3.22	-4.93	-3.19	4.50	5.39	1.70	-1.50	5.68	2.51	-4.76	-1.34
2023	3.75	-4.42	-1.02	3.83	3.24	2.65	-4.01	2.91	-6.07	-3.03	3.58	5.43	6.12
2024	6.17	4.45	5.86	-2.57	-1.29	1.42	5.26	3.35	-3.53	-2.00	1.67		19.74

NAV & PERFORMANCE DATA

RC2 (SEK) NAV													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	
2009						99.74	99.98	101.12	101.68	96.94	102.10	107.07	
2010	111.07	108.57	115.69	109.78	97.28	94.47	90.31	89.58	94.10	97.38	99.14	103.08	
2011	99.84	101.20	102.84	106.40	112.28	110.30	108.32	101.33	101.58	105.64	107.89	112.63	
2012	120.30	120.44	125.51	126.83	127.66	132.58	128.13	127.86	133.77	129.36	133.84	130.80	
2013	139.17	143.74	153.48	161.57	171.53	167.92	185.74	185.04	192.06	187.86	206.87	206.39	
2014	219.98	231.28	221.05	210.98	223.54	236.05	238.90	255.47	260.24	283.00	293.97	310.92	
2015	341.02	365.80	386.77	366.96	403.34	392.85	418.61	375.87	323.26	351.09	369.14	361.10	
2016	298.25	283.80	280.26	292.73	317.00	311.48	345.83	336.89	345.62	313.62	336.59	332.52	
2017	344.62	388.54	402.06	406.34	374.90	405.23	395.81	410.70	421.71	421.61	448.59	452.80	
2018	482.21	495.26	493.58	502.12	522.72	526.43	542.35	595.22	577.33	512.40	535.48	438.95	
2019	513.74	532.94	520.48	500.62	495.15	542.92	565.68	548.37	514.19	548.99	606.51	634.95	
2020	618.19	596.38	519.46	598.14	649.82	654.22	621.88	645.50	685.28	658.22	693.53	717.54	
2021	730.79	738.81	768.86	777.74	766.21	805.72	799.24	813.64	772.49	801.20	751.17	824.34	
2022	738.97	752.78	777.39	739.37	716.10	748.63	789.27	803.05	791.39	835.97	857.24	817.50	
2023	847.60	811.40	803.43	834.34	860.76	883.85	848.79	873.84	821.14	796.58	825.44	870.61	
2024	924.18	965.56	1022.52	996.74	984.31	998.70	1051.36	1086.94	1048.98	1028.38	1045.98		

RC2 (SEK) PERFORMANCE %. NET OF FEES													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	TOTAL
2009						-0.26	0.24	1.14	0.55	-4.66	5.32	4.87	7.07
2010	3.74	-2.25	6.56	-5.11	-11.39	-2.89	-4.40	-0.81	5.05	3.49	1.81	3.97	-3.73
2011	-3.14	1.36	1.62	3.46	5.53	-1.76	-1.80	-6.45	0.25	4.00	2.13	4.39	9.26
2012	6.81	0.12	4.21	1.05	0.65	3.85	-3.36	-0.21	4.62	-3.30	3.46	-2.27	16.13
2013	6.40	3.28	6.78	5.27	6.16	-2.10	10.61	-0.38	3.79	-2.19	10.12	-0.23	57.79
2014	6.58	5.14	-4.42	-4.56	5.95	5.60	1.21	6.94	1.87	8.75	3.88	5.77	50.65
2015	9.68	7.27	5.73	-5.12	9.91	-2.60	6.56	-10.21	-14.00	8.61	5.14	-2.18	16.14
2016	-17.41	-4.84	-1.25	4.45	8.29	-1.74	11.03	-2.59	2.59	-9.26	7.32	-1.21	-7.91
2017	3.64	12.74	3.48	1.06	-7.74	8.09	-2.32	3.76	2.68	-0.02	6.40	0.94	36.17
2018	6.50	2.71	-0.34	1.73	4.10	0.71	3.02	9.75	-3.01	-11.25	4.50	-18.03	-3.06
2019	17.04	3.74	-2.34	-3.82	-1.09	9.65	4.19	-3.06	-6.23	6.77	10.48	4.69	44.65
2020	-2.64	-3.53	-12.90	15.15	8.64	0.68	-4.94	3.80	6.16	-3.95	5.36	3.46	13.01
2021	1.85	1.10	4.07	1.15	-1.48	5.16	-0.80	1.80	-5.06	3.72	-6.24	9.74	14.88
2022	-10.36	1.87	3.27	-4.89	-3.15	4.54	5.43	1.75	-1.45	5.63	2.54	-4.64	-0.83
2023	3.68	-4.27	-0.98	3.85	3.17	2.68	-3.97	2.95	-6.03	-2.99	3.62	5.47	6.50
2024	6.15	4.48	5.90	-2.52	-1.25	1.46	5.27	3.38	-3.49	-1.96	1.71		20.14

ABOUT RHENMAN & PARTNERS

Rhenman & Partners Asset Management AB ("Rhepa") was founded in 2008 and is a Stockholm-based asset manager with a focus on the healthcare sector. Rhepa is responsible for the portfolio of a sector fund registered in Luxembourg: Rhenman Healthcare Equity L/S. The fund is managed by FundRock Management Company S.A. who has commissioned Rhepa to manage the fund's portfolio. Rhepa's experienced investment team is supported by a scientific advisory board consisting of medical experts with a global network of researchers and specialists.

Legal Disclaimer

Rhenman Healthcare Equity L/S ("the Fund") is not an investment fund as defined in the European Union directives relating to undertakings for collective investment in transferable securities (UCITS). Legal information regarding Fund is contained in the Prospectus and the KIID, available at Rhenman & Partners Asset Management AB (Rhenman & Partners) webpage: <http://rhepa.com/the-fund/prospectus/>.

This material has been prepared by Rhenman & Partners for professional and non-professional investors. Rhenman & Partners when preparing this information has not taken into account any one customer's particular investment objectives, financial resources or other relevant circumstances and the opinions and recommendations herein are not intended to represent recommendations of particular investments to particular customers. This material is for informational purposes only and should not be construed as an offer or solicitation to sell or buy units in the Fund. Investors are strongly recommended to get professional advice as to whether investment in the Fund is appropriate having considered particular investment needs, objectives and financial circumstances before investing.

All securities' transactions involve risks, which include (among others) the risk of adverse or unanticipated market, financial or political developments and, in international transactions, currency risk. There can be no assurance that an investment in the Fund will achieve profits or avoid incurring substantial losses. There is a high degree of risk inherent in investments and they may not be suitable for all eligible investors. It is possible that an investor may lose some or all of its investment. The past is not necessarily a guide to the future performance of an investment. The value of investments may fall as well as rise and investors may not get back the amount invested. Changes in rates of foreign exchange may cause the value of investments to go up or down.

Before making an investment decision, an investor and/or its adviser should (i) consider the suitability of investments in the Fund with respect to its investment objectives and personal situation and (ii) consider factors such as its personal net worth, income, age, risk tolerance and liquidity needs. Short-term investors and investors who cannot bear the loss of some or all of their investment or the risks associated with the limited liquidity of an investment should not invest.

Due care and attention has been used in the preparation of this information. However, actual results may vary from their forecasts, and any variation may be materially positive or negative. Forecasts, by their very nature, are subject to uncertainty and contingencies, many of which are outside the control of Rhenman & Partners. Rhenman & Partners cannot guarantee that the information contained herein is without fault or entirely accurate. There may be delays, omissions or inaccuracies in the information. Any dated information is published as of its date only and no obligation or responsibility is undertaken to update or amend any such information.

The information in this material is based on sources that Rhenman & Partners believes to be reliable. Rhenman & Partners can however not

guarantee that all information is correct. Furthermore, information and opinions may change without notice. Rhenman & Partners is under no obligation to make amendments or changes to this publication if errors are found or opinions or information change. Rhenman & Partners accepts no responsibility for the accuracy of its sources.

Rhenman & Partners is the owner of all works of authorship including, but not limited to, all design text, images and trademarks in this material unless otherwise explicitly stated. The use of Rhenman & Partners' material, works or trademarks is forbidden without written consent except where otherwise expressly stated. Furthermore, it is prohibited to publish material made or gathered by Rhenman & Partners without written consent.

By accessing and using the <http://rhepa.com/> website and any pages thereof, you acknowledge that you have reviewed the following important legal information and understand and agree to the terms and conditions set therein. If you do not agree to the terms and conditions in this disclaimer, do not access or use the <http://rhepa.com/> website in any way.

Products and services described herein are not available to all persons in all geographical locations. Rhenman & Partners will not provide any such products or services to any person if the provision of such services could be in violation of law or regulation in such person's home country jurisdiction or any other related jurisdiction. The units of the Fund may not be offered or sold to or within the United States or in any other country where such offer or sale would conflict with applicable laws or regulations.

In no event, including (but not limited to) negligence, will Rhenman & Partners be liable to you or anyone else for any consequential, incidental, special or indirect damages (including but not limited to lost profits, trading losses and damages).

The sole legally binding basis for the purchase of shares of the Fund described in this information is the latest valid sales prospectus with its terms of contract. Subscriptions cannot be received on the basis of financial reports.

An investment in the Fund does not represent deposits or other liabilities of any member of the Rhenman & Partners Group. Neither Rhenman & Partners nor any member of the Rhenman & Partners Group and its affiliates guarantees in any way the performance of the Fund, repayment of capital from the Fund, any particular return from or any increase in the value of the Fund.

The representative in Switzerland is FundRock Switzerland SA, Route de Cité-Ouest 2, 1196 Gland, Switzerland. The paying agent in Switzerland is Banque Cantonale de Genève (BCGE), 17 quai de l'Île, 1204 Geneva, Switzerland. The Prospectus, the Articles of Association and (annual and semi-annual report, if any) [annual financial statements] can be obtained free of charge from the representative in Switzerland. With regards to the Shares offered in Switzerland, the place of performance is the registered office of the representative and the place of jurisdiction is at the registered office of the representative or at the registered office or place of residence of the investor.

Subscribe:



NEWSLETTER

rhepa.com



WEBCAST

[YouTube](https://www.youtube.com)



PODCAST

[Spotify](https://open.spotify.com) | [Podcaster](https://www.podcaster.com) | [Podbean](https://www.podbean.com)

CONTACT DETAILS:

Rhenman & Partners
Asset Management AB
Strandvägen 5A
114 51 Stockholm, Sweden

T: + 46 8 459 88 80
E: info@rhepa.com

 **RHENMAN
& PARTNERS**
ASSET MANAGEMENT